Evidence, advice, guidance and standards

Healthcare Improvement Scotland is an authority on the development of evidence-based advice, guidance and standards.

We collaborate with national and international experts to identify, develop and share evidence for improvement. This evidence is accessible to healthcare professionals to support them in providing safe and effective care, and to the public to inform them of the quality of care they can expect to receive.

We also assess new technologies in healthcare through the Scottish Health Technologies Group, and the clinical and cost effectiveness of newly licensed medicines through the Scottish Medicines Consortium.

The national standards we develop use Scottish Intercollegiate Guidelines Network (SIGN) guidelines, and may also draw on sources such as National Institute for Health and Clinical Excellence (NICE) guidelines, evidence notes, health technology assessments and systematic reviews.

Following publication of our standards, we continue to work with NHS boards and voluntary organisations to support their implementation and, consequently, improvements to patient care.

Watch a short film about our evidence work


Share this content


Latest SHTG publications

  • What is the evidence for the clinical and cost effectiveness of single room only wards in hospitals compared with non-single room only wards?
    Evidence note

    Advice Statement
  • What is the published evidence on the accuracy, turnaround time and cost/cost effectiveness of tests to identify carbapenemase-producing Enterobacteriaceae (CPE) in hospital screening samples obtained from patients identified as at risk of CPE colonisation during clinical risk assessment?
    Evidence note
    Advcie Statement
  • What is the clinical effectiveness, safety and cost effectiveness of endovascular therapy using mechanical thrombectomy devices for patients with acute ischaemic stroke?
    Evidence note
    Advice Statement
  • What is the clinical effectiveness, cost effectiveness and safety of home health monitoring compared with usual care for patients with moderate to severe chronic obstructive pulmonary disease?
    Evidence note
    Advice Statement

Annual report

Annual report 2016
Read our annual report for 2015-2016
November 2016